JP2023107883A5 - - Google Patents

Download PDF

Info

Publication number
JP2023107883A5
JP2023107883A5 JP2023096692A JP2023096692A JP2023107883A5 JP 2023107883 A5 JP2023107883 A5 JP 2023107883A5 JP 2023096692 A JP2023096692 A JP 2023096692A JP 2023096692 A JP2023096692 A JP 2023096692A JP 2023107883 A5 JP2023107883 A5 JP 2023107883A5
Authority
JP
Japan
Prior art keywords
patient
composition
surgery
glp
parenteral nutrition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023096692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023107883A (ja
JP7752152B2 (ja
Filing date
Publication date
Priority claimed from JP2020526107A external-priority patent/JP7296958B2/ja
Application filed filed Critical
Publication of JP2023107883A publication Critical patent/JP2023107883A/ja
Publication of JP2023107883A5 publication Critical patent/JP2023107883A5/ja
Application granted granted Critical
Publication of JP7752152B2 publication Critical patent/JP7752152B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023096692A 2017-11-06 2023-06-13 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ Active JP7752152B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582055P 2017-11-06 2017-11-06
US62/582,055 2017-11-06
JP2020526107A JP7296958B2 (ja) 2017-11-06 2018-11-05 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020526107A Division JP7296958B2 (ja) 2017-11-06 2018-11-05 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ

Publications (3)

Publication Number Publication Date
JP2023107883A JP2023107883A (ja) 2023-08-03
JP2023107883A5 true JP2023107883A5 (enExample) 2024-03-06
JP7752152B2 JP7752152B2 (ja) 2025-10-09

Family

ID=66332372

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020526107A Active JP7296958B2 (ja) 2017-11-06 2018-11-05 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ
JP2023096692A Active JP7752152B2 (ja) 2017-11-06 2023-06-13 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020526107A Active JP7296958B2 (ja) 2017-11-06 2018-11-05 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ

Country Status (14)

Country Link
US (1) US11660328B2 (enExample)
EP (1) EP3706774A4 (enExample)
JP (2) JP7296958B2 (enExample)
KR (1) KR102825098B1 (enExample)
CN (1) CN111629745A (enExample)
AR (1) AR113835A1 (enExample)
AU (1) AU2018360744A1 (enExample)
BR (1) BR112020008936A2 (enExample)
CA (1) CA3079523A1 (enExample)
IL (1) IL274098B2 (enExample)
MX (1) MX2020004620A (enExample)
TW (1) TW201922279A (enExample)
WO (1) WO2019090209A1 (enExample)
ZA (1) ZA202002080B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7249492B2 (ja) * 2017-08-22 2023-03-31 タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド Glp-2融合ポリペプチドならびに消化管の状態を処置および予防するための使用
US20210355187A1 (en) * 2018-10-24 2021-11-18 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
US20230129788A1 (en) * 2020-03-30 2023-04-27 Zealand Pharma A/S Glp-1/glp-2 dual agonists
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ,インク. Ampkアクチベーター
WO2021263040A1 (en) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Stable peptibody formulations
CN115636876A (zh) * 2021-07-20 2023-01-24 重庆派金生物科技有限公司 胰高血糖素样肽-2突变体的定向化学偶联物及其应用
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025181330A1 (en) * 2024-02-29 2025-09-04 Vectivbio Ag Dosage regimens for glucagon-like peptide 2 (glp-2) analogs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1809318B1 (en) * 2004-11-01 2013-06-12 NPS Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US20090175795A1 (en) 2005-07-29 2009-07-09 Amprotein Corporation Chimeric therapeutic agents
WO2007067828A2 (en) * 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
JP5290177B2 (ja) * 2006-08-31 2013-09-18 セントカー・インコーポレーテツド Glp−2ミメティボディ、ポリペプチド、組成物、方法および用途
JP2008247789A (ja) * 2007-03-30 2008-10-16 Kissei Pharmaceut Co Ltd クローン病に伴う腸管狭窄の進展抑制用医薬組成物
PT2755675T (pt) 2011-09-12 2018-10-11 Amunix Operating Inc Composições de péptido semelhante a glucagão-2 e métodos para produzir e utilizar as mesmas
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
KR101895047B1 (ko) 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
CN106029087A (zh) * 2013-12-20 2016-10-12 印第安纳大学研究及科技有限公司 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2023107883A5 (enExample)
IL274098B2 (en) Glp-2 analogs and peptibodies for administration before during, or after surgery
Bywaters Heel lesions of rheumatoid arthritis
Buchwald et al. Ileal bypass in patients with hypercholesterolemia and atherosclerosis: preliminary report on therapeutic potential
Sharma et al. Course of pulmonary sarcoidosis with and without corticosteriod therapy as determined by pulmonary function studies
JP2021502389A5 (enExample)
Braier et al. Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone
Halloun et al. Bariatric surgery in adolescents with obesity: long-term perspectives and potential alternatives
JP2019112416A5 (enExample)
JP2019530648A5 (enExample)
Han et al. Management of eosinophilic granuloma occurring in the appendicular skeleton in children
Zemskov et al. Efficacy of Ukrain in the treatment of pancreatic cancer
Pelz et al. A case of pre-chronic paroxysmal hemicrania
Tham et al. Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer
van Laar et al. High-dose immunosuppressive therapy and autologous progenitor cell transplantation for systemic sclerosis
Chin et al. Cerebellar glioblastoma in childhood
Boland V. Clinical Experience with Nitrogen Mustard in Hodgkin's Disease
Hanna et al. Efficacy and complications of intravesical BCG in immunocompromised patients
Katsube et al. Interposition grafting of collagen-gelatin sponge impregnated with basic fibroblast growth factor in primary palatoplasty
Kaddioui et al. Pansclerotic morphea: a historical case in children
Greenberg et al. Current and emerging multiple sclerosis therapeutics
Elbrønd et al. Circinoma Linguae: A series of 96 patients
Haque et al. Oral Propranolol and Prednisolone in the Treatment of Infantile Hemangioma: A Comparative Study
Akhyar et al. Clinical features and evaluation of systemic sclerosis: A dermatology-based case series
JPWO2021080983A5 (enExample)